{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The number of participants who received at least two cycles of the triplet neoadjuvant therapy getting at least one dose of maintenance therapy.","groups":[{"description":"NEOADJUVANT: Patients receive atezolizumab IV over 30-60 minutes, pemetrexed disodium IV over 10 minutes, and cisplatin IV over 2 hours on day 1. Cycles repeats every 21 days for 4 cycles in the absence of disease progression or unexpected toxicity.\n\nSURGERY: Within 21-90 days after completion of neoadjuvant therapy, patients undergo extrapleural pneumonectomy (EPP) or pleurectomy/decortication (PD). Patients who undergo EPP will then undergo radiation therapy.\n\nMAINTENANCE: Within 90 days after completion of either PD or radiation (post-EPP), patients receive atezolizumab IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 1 year in the absence of disease progression or unexpected toxicity.","id":"OG000","title":"Treatment (Chemotherapy, Surgery +/- RT, Maintenance)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants that received at least 2 cycles of neoadjuvant Cisplatin-Pemetrexed-Atezolizumab.","reportingStatus":"POSTED","timeFrame":"Duration of treatment until first dose of maintenance therapy. Includes 21 day cycles of neoadjuvant chemo and surgery - extrapleural pneumonectomy or pleurectomy/decortication (radiation therapy for participants who received extrapleural pneumonectomy).","title":"Feasibility of Neoadjuvant Cisplatin-Pemetrexed-Atezolizumab, Surgery +/- Radiation, and Maintenance Therapy.","type":"PRIMARY","unitOfMeasure":"Participants"}